NCT02724085View on ClinicalTrials.gov

A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271

PHASE1CompletedINTERVENTIONAL
Enrollment

57

Participants

Timeline

Start Date

December 18, 2015

Primary Completion Date

September 28, 2016

Study Completion Date

December 12, 2016

Conditions
Pneumonia
Interventions
DRUG

TP-271

TP-271 is a novel, broad-spectrum tetracycline with potent activity against multidrug-resistant pathogens. It will be administered intravenously (IV) in doses ranging from 0.15 to 5.0 mg/kg

Trial Locations (1)

78744

PPD Phase 1 Clinic, Austin

All Listed Sponsors
collaborator

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

lead

Tetraphase Pharmaceuticals, Inc

INDUSTRY

NCT02724085 - A Phase 1 Study to Assess the Safety, Tolerability and PK of IV TP-271 | Biotech Hunter | Biotech Hunter